Journal article
Spleen volume variation in patients with locally advanced non-small cell lung cancer receiving platinum-based chemo-radiotherapy
SW Wen, SJ Everitt, J Bedo, M Chabrot, DL Ball, B Solomon, M MacManus, RJ Hicks, A Möller, A Leimgruber
Plos One | Published : 2015
Abstract
There is renewed interest in the immune regulatory role of the spleen in oncology. To date, very few studies have examined macroscopic variations of splenic volume in the setting of cancer, prior to or during therapy, especially in humans. Changes in splenic volume may be associated with changes in splenic function. The purpose of this study was to investigate variations in spleen volume in NSCLC patients during chemo-radiotherapy. Sixty patients with stage I-IIIB NSCLC underwent radiotherapy (60Gy/30 fractions) for six weeks with concomitant carboplatin/paclitaxel (Ca/P; n = 32) or cisplatin/etoposide (Ci/E; n = 28). A baseline PET/CT scan was performed within 2 weeks prior to treatment and..
View full abstractGrants
Awarded by International Business Machines Corporation
Funding Acknowledgements
AL, AM and SE are supported by The CASS Foundation (SM/12/4249/RMR: DR; www.cassfoundation.org). AM and AL are supported by the National Health and Medical Research Council (www.nhmrc.gov.au) project grant APP106851, Cancer Council Queensland grant (APP1045260; www.cancerqld.org.au), and a National Breast Cancer Foundation Australia grant (NC-13-26; www.nbcf.org.au/) and fellowship to AM (ECF-11-09). SE is supported by NHMRC (www.nhmrc.gov.au) grant APP1003895. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder IBM Australia provided support in the form of salaries for Dr Justin Bedo, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr Bedo also holds an adjunct position at The University of Melbourne, Australia, as indicated in the manuscript.